AI-generated research brief — verify at source
Affective Touch Improves Existential Distress and Quality of Life in Advanced Cancer
In a randomized controlled trial of 83 patients with advanced cancer, daily affective touch for 2 weeks significantly reduced existential distress (mean score 6.60 versus 8.15 in controls, p < 0.05) and improved quality of life (mean score 57.24 versus 50.24 in controls, p < 0.001). The intervention also provided immediate relief from pain after each session, though this effect did not persist at 1- or 2-week assessments.
What Was Studied
Researchers investigated whether affective touch—a form of gentle, intentional physical contact—could reduce the substantial physical and psychological burden experienced by patients with advanced cancer. The study specifically examined effects on existential distress, pain levels, and overall quality of life, outcomes that are critical for end-of-life care but often inadequately addressed by pharmacological interventions alone.
How It Was Studied
This randomized controlled trial enrolled 83 patients with advanced cancer, randomly assigning them to receive either affective touch intervention or routine care. The experimental group received affective touch once daily for 14 consecutive days as an adjunct to standard nursing care. Researchers collected baseline demographic data and administered validated assessment tools before the intervention began. Existential distress was measured using the Existential Distress Scale, while quality of life was assessed with the Functional Assessment of Cancer Therapy-General instrument, both administered before and after the 2-week intervention period. Pain measurements were more frequent: average pain levels from the Brief Pain Inventory were collected at baseline, week 1, and week 2, while current pain levels were recorded daily immediately following each affective touch session.
What Was Observed
- After 2 weeks, patients receiving affective touch showed lower existential distress compared to controls, with mean scores indicating a modest but statistically significant improvement (6.60 ± 2.75 versus 8.15 ± 2.23, p < 0.05). Lower scores on this scale indicate reduced distress.
- Quality of life improved substantially in the intervention group, with mean scores approximately 14% higher than controls at the end of the study period (57.24 ± 14.26 versus 50.24 ± 12.35, p < 0.001). This difference exceeded the typical threshold for clinical meaningfulness on this assessment tool.
- Affective touch produced immediate pain relief measured directly after each daily session. However, when researchers examined pain scores at the 1-week and 2-week timepoints—which captured pain levels independent of the immediate post-session period—no statistically significant long-term analgesic effect was detected.
Why This Matters
This trial provides empirical support for incorporating affective touch as a non-pharmacological intervention in advanced cancer care settings. The findings are particularly relevant given the limited effectiveness and side-effect burden of many medications used to manage existential distress and psychological suffering in terminally ill patients. The intervention requires no specialized equipment, minimal training, and can be delivered by oncology nurses within existing care workflows. These characteristics make it a practical option for broader implementation, especially in resource-limited settings where access to specialized palliative care services may be constrained.
How to Read This Result
The positive effects on existential distress and quality of life appear robust and clinically meaningful, though the moderate sample size and single-center nature of the trial warrant cautious interpretation and replication in diverse populations and care settings before widespread adoption recommendations.
Limitations
The most notable limitation is the temporal specificity of pain relief: while affective touch reduced pain immediately after each session, this benefit did not translate into sustained improvements when assessed at 1- or 2-week intervals. This pattern suggests that any analgesic effect may be transient and context-dependent, raising questions about optimal dosing, session duration, or whether pain relief requires contemporaneous touch rather than cumulative exposure. The abstract does not specify blinding procedures, control group activities beyond “routine care,” or whether outcome assessors were masked to group assignment—all factors that could influence the magnitude of observed effects.